Simulations Plus (NASDAQ:SLP) Stock Crosses Above 200-Day Moving Average - Here's What Happened

Key Points

• Simulations Plus shares crossed above their 200-day moving average, reaching $18.42 compared with the $16.21 average, on volume of 104,375 shares.
• Analyst sentiment remains cautious: seven analysts rate the stock Hold and one rates it Sell, producing a consensus rating of “Reduce” and an average price target of $17.25.
• The company exceeded quarterly expectations, reporting $0.30 in EPS versus the $0.23 estimate and revenue of $21.89 million versus the $20.90 million consensus.

Shares of Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $16.21 and traded as high as $18.42. Simulations Plus shares last traded at $18.42, with a volume of 104,375 shares.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on SLP shares. Weiss Ratings upgraded Simulations Plus from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, July 10th. William Blair lowered Simulations Plus from an "outperform" rating to a "market perform" rating in a research note on Wednesday, June 17th. Wall Street Zen lowered Simulations Plus from a "buy" rating to a "hold" rating in a research note on Saturday, June 13th. Finally, Craig Hallum cut Simulations Plus from a "buy" rating to a "hold" rating and set a $18.50 target price for the company. in a report on Thursday, June 18th. Seven equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $17.25.

Simulations Plus Stock Performance

The firm has a fifty day moving average of $18.36 and a 200-day moving average of $16.21. The stock has a market capitalization of $372.64 million, a price-to-earnings ratio of 46.05 and a beta of 1.33.

Simulations Plus (NASDAQ:SLP - Get Free Report) last issued its quarterly earnings data on Thursday, July 9th. The technology company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.07. Simulations Plus had a return on equity of 13.50% and a net margin of 9.88%.The company had revenue of $21.89 million for the quarter, compared to analysts' expectations of $20.90 million.

Insider Buying and Selling

In related news, Director Walter Woltosz sold 4,177 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $18.44, for a total transaction of $77,023.88. Following the transaction, the director directly owned 3,202,131 shares of the company's stock, valued at approximately $59,047,295.64. The trade was a 0.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 19.10% of the company's stock.

Institutional Trading of Simulations Plus

Large investors have recently bought and sold shares of the company. Meros Investment Management LP acquired a new position in shares of Simulations Plus during the second quarter worth $2,384,493. First Light Asset Management LLC boosted its stake in shares of Simulations Plus by 6.1% in the second quarter. First Light Asset Management LLC now owns 2,792,677 shares of the technology company's stock valued at $51,134,000 after purchasing an additional 159,854 shares during the period. Polar Asset Management Partners Inc. acquired a new stake in Simulations Plus during the 2nd quarter valued at $2,341,000. Renaissance Technologies LLC grew its holdings in Simulations Plus by 807.5% during the 1st quarter. Renaissance Technologies LLC now owns 181,500 shares of the technology company's stock valued at $2,145,000 after purchasing an additional 161,500 shares in the last quarter. Finally, Groupe la Francaise purchased a new stake in Simulations Plus during the 2nd quarter worth $2,329,000. Institutional investors and hedge funds own 78.08% of the company's stock.

About Simulations Plus

Simulations Plus, Inc develops software and provides consulting services for pharmaceutical and biotechnology companies involved in drug discovery and development. Its modeling and simulation tools are designed to help researchers evaluate drug candidates, understand how medicines move through the body, assess safety risks and support decisions throughout the development process.

The company's products include GastroPlus, a platform used for physiologically based pharmacokinetic and biopharmaceutic modeling; ADMET Predictor, which helps predict absorption, distribution, metabolism, excretion and toxicity characteristics; and DILIsym, a software platform focused on drug-induced liver injury.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.